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The effect of using different embolic agents on survival in 
transarterial chemoembolization of hepatocellular carcinoma: 
gelfoam versus polyvinyl alcohol




We aimed to compare the effect of using different embol-
ic agents such as gelfoam and polyvinyl alcohol (PVA) on 
survival, tumor response, and complications in transarteri-
al chemoembolization (TACE) of hepatocellular carcinoma 
(HCC) patients. 
MATERIALS AND METHODS
We retrospectively reviewed the medical records of 38 inop-
erable HCC patients who underwent TACE between August 
1998 and April 2007. A total of 50 TACE sessions were per-
formed using PVA (n=18) or gelfoam particles (n=20), follow-
ing the application of 60 mg doxorubicin with 10–20 mL lip-
iodol emulsion. The PVA and gelfoam groups were compared 
based on clinical, laboratory, and demographic variables. Sur-
vival rates were calculated starting from the first TACE session 
using the Kaplan-Meier analysis. 
RESULTS
There was no significant difference between the survival rates 
of PVA and gelfoam groups (P = 0.235). Overall survival rates 
at 12, 24, 36, 48, and 60 months were 55%, 36%, 15%, 7%, 
and 5%, respectively. Tumor response, age, lipiodol accumu-
lation type, number of HCC foci, complications, and serum 
alpha-fetoprotein level were significant factors for survival in 
all patients. 
CONCLUSION
Use of gelfoam or PVA as the embolic agent did not have a 
significant impact on survival. Complete tumor response, in-
tensive lipiodol accumulation in tumor, older age (>60 years), 
fewer (≤3) HCC foci, and low serum alpha-fetoprotein level 
(≤400 ng/mL) were found to improve cumulative survival 
significantly. 
H epatocellular carcinoma (HCC) is the most common primary ma-lignant tumor of the liver and the third leading cause of cancer death worldwide. More than 90% of HCC occurs following liver 
cirrhosis (1). Transplantation, ablative treatments, and surgical resec-
tion are considered as curative treatments (2). Unfortunately, only 30% 
of HCC cases are eligible for these curative treatments at the time of 
diagnosis, while the majority is diagnosed in advanced stage, beyond 
the criteria for surgical therapy (3, 4). Transarterial chemoembolization 
(TACE) remains the most widely used and established palliative treat-
ment in the management of patients with advanced HCC, with proven 
survival benefits over the best supportive care (5−8). Despite the world-
wide acceptance of TACE in the treatment of surgically unresectable 
HCC, there is still no standard protocol for its use (9). Various TACE 
techniques which comprise selective or superselective catheterization, 
different chemotherapeutic regimens (doxorubicin, 5-fluorouracil, cis-
platin, mytomycin-c, epirubicin, neocarzinostatin), and different embo-
lization agents can influence the patient outcome (10, 11). Furthermore 
a previous review stated that polyvinyl alcohol (PVA) particles may be 
better than gelatin sponge in TACE treatment (12). Thus, the primary 
aim of our study was to compare the effect of different embolic agents 
such as PVA and gelfoam on survival and patient outcome in the treat-
ment of surgically unresectable HCC. The secondary aim was to investi-
gate the effect of TACE on survival. 
Materials and methods
Patient selection
We retrospectively reviewed 38 HCC patients (28 men, 10 women; 
mean age, 62.8±12.4 years) who underwent TACE between August 1998 
and April 2007 in our institution. The study protocol was approved by 
the local ethics committee, and all patients gave a written informed con-
sent before the procedure. Patients with surgically unresectable HCC 
were evaluated by an oncology board and underwent TACE procedure 
upon the decision of this board. Patients with surgically unresectable 
HCC, with or without portal branch throm bosis, and without previous 
TACE treatment were included in the study. Patients with main portal 
vein throm bosis, hepatic failure, or extrahepatic metastasis were exclud-
ed. History of concomittant radiofrequency ablation (RFA) or percutane-
ous ethanol injection (PEI) was not a criterion for exclusion. Doxorubi-
cin (60 mg) with lipiodol emulsion (10−20 mL) was administered to all 
patients before embolization. Twenty patients underwent embolization 
with gelfoam and 18 patients underwent embolization with PVA. Two 
patients in gelfoam group had previous PEI and RFA treatments. Two pa-
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tients in the gelfoam group underwent 
additional PEI, and two patients in the 
PVA group underwent additional RFA. 
Medical records were obtained from 
the hospital information system, and 
radiological data were retrieved using 
the picture archiving and communica-
tion system. 
Chemoembolization procedure and 
technique 
All patients underwent triple phase 
multidetector CT (unenhanced, arteri-
al and venous phases) within a month 
before the TACE session. CT examina-
tions were performed using a 16-detec-
tor CT (Brilliance 16, Philips Medical 
Systems, Best, the Netherlands) in su-
pine position. Axial scanning param-
eters were as follows: tube voltage, 
120 kV; mAs, 300; collimation, 16×1.5 
mm; matrix, 512×512; rotation time, 
0.75 s; pitch, 0.93; FOV, 40 cm; slice 
thickness, 5 mm. 
All patients were preprocedurally 
starved at least eight hours and hydrat-
ed with 150−200 mL/h of normal sa-
line solution. TACE was performed by 
interventional radiologists (O.D. and 
A.Y.G.) who had similar experience 
and expertise in the management of 
HCC. Superior mesenteric angiography 
was performed to determine the por-
tal venous patency and possible right 
hepatic arterial variations. Then, right 
and left hepatic angiography was per-
formed to determine the tumor-bear-
ing artery for drug administration. 
After selective or superselective cath-
eterization of the distal feeding artery 
with a microcatheter (Progreat, Teru-
mo, Tokyo, Japan), doxorubicin (Adri-
blastine, Pfizer, Nerviano, Italy) (1 mg/
kg of weight, maximum 60 mg) mixed 
with 10−20 mL of iodized oil emulsion 
(Lipiodol, Guerbet, Aulnay-sous-Bois, 
France) and 10 mL of contrast agent 
(Ultravist 300/100 mL Bayer Schering 
Pharma, Berlin, Germany) was admin-
istered in all patients before the embo-
lization step. After the administration 
of lipiodol chemotherapy, emboliza-
tion was performed using  1−2 mm di-
ameter gelfoam particles (Gelitaspon, 
Gelita Medical BV, Amsterdam, the 
Netherlands) or 150−250 µm PVA par-
ticles. Injection of lipiodol chemother-
apy and embolization were performed 
under realtime floroscopy to avoid the 
reflux of the injected material. When 
the flow slowed down significantly 
with stagnation, embolization was 
stopped for a while to allow flow res-
toration. Then embolization was rein-
stated until complete occlusion of the 
feeding artery was achieved. 
Tumor response assessment
Tumor response was assessed on 
multiphase contrast-enhanced CT, one 
month after the TACE session. In one 
patient follow-up imaging was per-
formed by magnetic resonance imag-
ing (MRI) due to renal functional dis-
order. An abdominal radiologist with 
a six-year experience, who was blinded 
to TACE technique, reviewed the CT 
and MRI data. We used the modified 
RECIST criteria (13, 14) to assess the 
tumor response as follows: complete 
response, elimination of any intratu-
mor arterial enhancement in all target 
lesions; partial response, at least 30% 
decrease in the sum of the largest di-
ameters of viable target lesions; stable 
disease, any cases which do not qualify 
for either partial response or progres-
sive disease; and progressive disease, 
at least 20% increment in the sum of 
the largest diameters of viable target 
lesions. Progressive disease was also 
noted when one or more new lesions 
were detected. Viable lesions were de-
fined by the presence of an enhanced 
area inside the tumor at arterial phase. 
Lipiodol deposition was also semi-
quantitatively assessed by opacifica-
tion on unenhanced CT. Four types 
of lipiodol deposition were defined as 
follows: type 1, diffuse homogeneous 
opacification of the tumor focus; type 
2, mostly homogeneous opacification; 
type 3, weak heterogeneous opacifica-
tion; type 4, very weak or no opacifica-
tion of the tumor focus (15). 
Additional TACE session was per-
formed if tumor enhancement was 
determined on follow-up CT. TACE 
session was performed twice in 10 pa-
tients (26.3%), and three times in six 
patients (15.8%). If there was no en-
hancement of the tumor, patients un-
derwent screening with repeat CT im-
aging performed every three months. 
Assessment parameters
Potential prognostic factors of tumor 
response and survival were analyzed, 
including patient characteristics such 
as age and gender, cirrhosis etiology, 
serum alanine and aspartate amino-
transferases, total serum bilirubin, al-
bumin, prothrombin time, Child-Pugh 
class, Okuda class; tumor characteris-
tics such as tumor size and number, 
portal vein thrombosis, serum al-
pha-fetoprotein (AFP); procedure-re-
lated factors such as TACE technique, 
type of embolization agent; short-term 
post-therapeutic evaluation such as 
postembolization syndrome, tumor 
response, tumor lipiodol fixation, liver 
failure, and long-term evaluation such 
as the number of TACE sessions, and 
the date of death.
Statistical analysis
Overall survival was evaluated by 
Kaplan-Meier curves and compared 
between groups using the log rank 
test. The univariate analysis for over-
all survival was performed using the 
log-rank test on Kaplan-Meier curves 
for categorical variables and the uni-
variate Cox Model for continuous 
variables. Results were expressed as 
mean±standard deviation. Chi-square 
and Mann-Whitney U tests were used 
in comparison of categorical and con-
tinuous variables, respectively. 
To determine factors affecting sur-
vival, continuous variables and some 
multinomial categorical variables were 
dichotomized as follows: percentage of 
hepatic involvement ≤50% vs. >50%, 
tumor diameter ≤5 cm vs. >5 cm, num-
ber of HCC foci ≤3 vs. >3, aspartate 
aminotransferase level ≤63 U/L vs. >63 
U/L, AFP level ≤400 ng/mL vs. >400 
ng/mL, age ≤60 years vs. >60 years 
(16), number of TACE sessions ≤1 and 
>1, type of lipiodol accumulation (type 
1 vs. the other types), type of tumor re-
sponse (type 4 vs. the other types).
A P value less than 0.05 was con-
sidered as statistically significant. The 
statistical software used was Statistical 
Package for Social Sciences, version 17 
(SPSS Inc., Chicago, Illinois, USA). 
Results
Thirty-eight patients underwent 
TACE treatment in the study period; 
all subjects died in the course of the 
study. One patient underwent liver 
transplantation in the follow-up peri-
od, but he died right after the trans-
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plantation surgery. Overall survival 
rates for the whole study group was 
55%, 36%, 15%, 7%, and 5% at 12, 
24, 36, 48, and 60 months respective-
ly. Mean survival of the whole group 
was 18.7±18.2 months (range, 1–72 
months).
The gelfoam and PVA groups were 
similar in all factors except in Child-
Pugh and Okuda classification (Table 
1). The PVA group had significant-
ly more patients in Child-Pugh A (P 
= 0.01) and Okuda class I (P = 0.04). 
However this result did not effect the 
duration of follow-up (P = 0.79) or the 
survival rates of the two groups (P = 
0.235). Survival rates at 12, 24, 36, 48 
and 60 months were 66%, 44%, 16%, 
11%, and 5% for PVA the group and 
45%, 30%, 15%, 5%, and 5% for the 
gelfoam group (Figure).
A total of 60 TACE sessions (mean, 
1.5) were performed in 38 patients. 
Twenty patients in the gelfoam group 
underwent 29 sessions (mean, 1.4) and 
18 patients in the PVA group under-
went 31 sessions (mean, 1.7) (P = 0.18). 
Prognostic factor analysis for surviv-
al is shown in Table 2. Patients with ≤3 
HCC nodules (n=29) had significant-
ly better survival than patients with 
>3 HCC nodules (n=9); survival rates 
at 12, 24, 36, 48 and 60 months were 
58%, 44%, 20%, 10%, and 6% for pa-
tients with ≤3 HCC nodules and 44%, 
11%, 0%, 0%, and 0% for patients with 
>3 HCC nodules (P = 0.023); mean sur-
vival was 21 months and nine months, 
respectively. 
Patients with AFP levels ≤400 ng/mL 
(n=31) had significantly better surviv-
al than patients with AFP levels >400 
ng/mL (n=7); survival at 12, 24, 36, 48 
and 60 months were 64%, 45%, 19%, 
9%, and 6% for patients with AFP ≤400 
ng/mL and 14%, 0%, 0%, 0%, and 0%, 
for patients with AFP >400 ng/mL (P < 
0.001); mean survival was 31 months 
and 17 months, respectively. 
Ten patients developed complications 
other than postembolectomy syndrome 
after the TACE session. Of these, four 
patients died due to hepatic failure 
within 30 days, and one patient died 
due to gastrointestinal bleeding within 
three days after the TACE, leading to 
an overall mortality rate of 13%. Two 
of these five patients were in the gel-
foam group (10% of that group); both 
had Child-Pugh B disease with massive 
ascites and large tumor sizes exceeding 
10 cm in diameter. The remaining three 
patients were in the PVA group (16% 
of that group); two patients had Child-
Pugh C and one patient had Child A 
disease. One patient developed an in-
trahepatic abscess, which healed after 
insertion of a drainage catheter. We 
also observed peritonitis (n=1), pleural 
effusion (n=1), ascites and encephalop-
athy (n=1), and transient increase in 
liver enzymes (n=1) in the TACE study 
group. Patients with (n=10) and without 
(n=28) complications had significantly 
different survival rates at 12, 24, 36, 48 
and 60 months (20%, 10%, 0%, 0%, and 
0% vs. 67%, 42%, 17%, 7%, and 3%; 
P < 0.001). Mean survival was 11 months 
in patients with complications and 20 
months in patients without complica-
tions. 
Survival was also analyzed in terms 
of lipiodol accumulation type. Five 
patients who did not have follow-up 
CT due to early mortality within one 
Table 1. Characteristics of patients undergoing the TACE procedure
 Total PVA Gelfoam P
Patients, n 38 18 20 
Age (years), mean±SD 62.8±12.4 61±15 63±9.2 0.83
Male gender, % 73.7 77.8 70 0.35
Etiology, %    0.36
  HBV 47.4 55.6 40 
  HCV 39.5 33.3 45 
  Other 13.2 11.1 15 
Child-Pugh class, %    0.01
  A 52.6 77.8 30 
  B 39.5 11.1 65 
  C 7.9 11.1 5 
Okuda class, %    0.04
  I 44.7 66.7 25 
  II 47.4 22.2 70 
  III 7.9 11.1 5 
Maximum HCC size (mm), mean±SD 63.3±45.5 64±53.8 62.8±38 0.48
Number of HCC foci, mean±SD 2.1±1.2 1.9±1.2 2.3±1.2 0.37
Bilirubin (mg/dL), mean±SD 2.4±2.1 2.5±3 2.3±0.7 0.18
Albumin (g/dL), mean±SD 3.2±0.7 3.4±0.7 3.0±0.7 0.07
AST (U/L), mean±SD 101.9±145.1 105.7±173.9 98.5±118 0.35
ALT (U/L), mean±SD 100.3±200.5 126.4±282.5 76.9±75.3 0.69
AFP (ng/mL), mean±SD 794±3269 210.2±331.3 1319±4483 0.95
PT (s), mean±SD 15.9±4.9 14.7±3.8 16.9±5.7 0.38
Number of TACE sessions, mean±SD 1.5±0.7 1.7±0.7 1.4±0.7 0.18
Technique, n    0.64
  Selective 12 6 6 
  Superselective 26 12 14 
PES, % 50 44.4 55 0.52
Complication, % 26.3 16.7 35 0.20
Follow-up (months), mean±SD 15.1±14 14.7±11.3 15.4±16.3 0.79
PVA, polyvinyl alcohol; n, number of patients; SD, standard deviation; HBV, Hepatitis B virus; HCV, Hepatitis C vi-
rus; HCC, hepatocellular carcinoma; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha-fe-
toprotein; PT, prothrombin time; TACE, transarterial chemoembolization; PES, postembolectomy syndrome.
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month and one patient who had fol-
low-up MRI instead of CT were ex-
cluded from this analysis. Survival of 
patients with type 1 accumulation 
(n=9) was significantly better than pa-
tients with type 2, 3 or 4 accumulation 
(n=23); survival rates at 12, 24, 36, 48 
and 60 months were 88%, 77%, 55%, 
22%, and 22% for type 1 lipiodol accu-
mulation and 52%, 26%, 4%, 4%, and 
4% for other types of lipiodol accumu-
lation (P = 0.026); mean survival was 
35 months and 15 months, respective-
ly. The relationship between lipiodol 
accumulation type and selectivity of 
the TACE was significant, such that 
superselective embolization improved 
type 1 lipiodol accumulation. A similar 
relationship was also present between 
type 1 lipiodol acumulation and com-
plete tumor response. 
Tumor response is an important 
factor of TACE success and complete 
response is the main goal of the treat-
ment. Patients with complete response 
(n=10) had significantly better survival 
compared with other types of response 
(n=23). Again five patients with ear-
ly mortality were excluded from this 
analysis. Survival rates at 12, 24, 36, 
48 and 60 months were 70%, 60%, 
50%, 30%, and 20% in patients with 
complete response and 60%, 34%, 4%, 
0%, and 0% for patients with other re-
sponse (P = 0.009). 
Older patients (>60 years, n=26) had 
better survival than younger patients 
(≤60 years, n=12); survival rates at 12, 
24, 36, 48 and 60 months were 65%, 
46%, 23%, 11%, and 7% for patients 
>60 years and 33%, 16%, 0%, 0%, and 
0% for patients ≤60 years (P = 0.014); 
mean survival was 22 months vs. 10 
months, respectively. 
Discussion
Our results showed no significant 
difference in survival of HCC patients 
treated with TACE using PVA or gel-
foam. Furthermore there was no signif-
icant difference between PVA and gel-
foam groups in terms of complication, 
postembolectomy syndrome, and the 
number of TACE sessions. Complete 
tumor response to treatment, type 1 
lipiodol accumulation, older age (>60 
years), low number of tumor foci (≤3), 
and low levels of serum AFP (≤400 ng/
mL) were prognostic factors signifi-
Table 2. Effect of variables on survival
Variables n P
Liver involvement (%), ≤50/>50 33/5 0.820
Tumor diameter (cm), ≤5/>5 23/15 0.946
HCC foci, ≤3/>3 29/9 0.023a
Child-Pugh class, A/B/C 20/15/3 0.096
Okuda class, I/II/III 17/18/3 0.122
AST (U/L), ≤63/>63 18/20 0.376
AFP (ng/mL), ≤400/>400  31/7 <0.001a
Portal vein thrombosis, yes/no 3/35 0.450
Embolic agent, PVA/gelfoam 18/20 0.235
Technique, selective/superselective 12/26 0.579
PES, yes/no 20/18 0.139
Complication, yes/no 10/28 <0.001a
Etiology, HBV/HCV/other 18/15/5 0.316
Lipiodol accumulation type, type 1/other types 9/23 0.026a
Tumor response type, type 4/other types 10/23 0.009a
Gender, female/male 10/28 0.762
Systemic disease, yes/no 14/24 0.731
Age (years), ≤ 60/>60 12/26 0.014a
Number of TACE sessions, 1/>1 22/16 0.512
RFA, yes/no 4/34 0.400
PEI, yes/no 4/34 0.169
n, number of patients; HCC, hepatocellular carcinoma; AST, aspartate aminotransferase; AFP, alpha-fetopro-
tein; PVA, polyvinyl alcohol; PES, postembolectomy syndrome; HBV, Hepatitis B virus; HCV, Hepatitis C virus; 
TACE, transarterial chemoembolization; RFA, radiofrequency ablation; PEI, percutaneous ethanol injection.
aP < 0.05.
Figure. Kaplan-Meier survival curve of patients who underwent transarterial 
chemoembolization with polyvinyl alcohol (PVA) or gelfoam. Dashed line indicates the PVA 
group; solid line represents the gelfoam group. Mean survival was 21.8±18.7 months (95% 
confidence interval [CI], 13–30 months) for the PVA group and 15.9±17.9 months (95% CI, 
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cantly associated with higher survival 
rates. Although superselectivity of em-
bolization was not a significant factor 
on survival, it was a significant indi-
cator of type 1 lipiodol accumulation, 
and it can be speculated that selectivi-
ty indirectly improves survival. 
The benefits reported in two pro-
spective randomized controlled pilot 
trials secured the role of TACE in the 
treatment of HCC (5, 17). Lo et al. (17) 
compared TACE (using cisplatin, lipi-
odol, and gelfoam) with symptomatic 
treatment, and determined the survival 
rates at 12, 24, and 36 months as 57%, 
31%, and 26%, vs. 32%, 11%, and 3%, 
respectively. Llovet et al. (5) compared 
TACE (using doxorubicin, lipiodol, and 
gelfoam), transarterial embolization 
(TAE) (using gelfoam), and symptom-
atic treatment groups; TACE group had 
the best survival rates at 12, 24, and 36 
months (82%, 63%, and 29%) com-
pared with TAE (75%, 50%, and 29%), 
and symptomatic treatment groups 
(63%, 27%, and 17%). In our study the 
survival rates at 12, 24, and 36 months 
were 55%, 36% and 15%. Our results 
were similar with those of Lo et al. 
(17), but lower than those reported by 
Llovet et al. (5). This difference can be 
attributed to better overall condition of 
the patients in Llovet et al., with the 
majority of the patients having Child-
Pugh A score, small tumor size and 
good clinical condition. 
Previous studies investigated the 
effect of different chemoterapeutic 
agents used in TACE on survival. Lo 
et al. (17) used 30 mg of cisplatin, Ll-
ovet et al. (5) administered doxorubi-
cin at varying doses based on serum 
bilirubin levels, and Barone et al. (18) 
used a mixture of 20–30 mg of doxo-
rubicin and 6–10 mg of mitomycin C 
with gelfoam. There is no clear answer 
for the optimal agents or doses applied 
in TACE (9). In our study, doxorubi-
cin and lipiodol emulsion was used in 
both PVA and gelfoam groups.
Embolization is an important aspect 
of transarterial treatment, especially in 
HCC patients, since it leads to damage 
and necrosis in the tumor through ar-
terial occlusion (19). Various embolic 
agents can be used in TACE such as 
coils, degradable starch microspheres, 
autologous blood clot, gelfoam, PVA, 
and powderized herbs (12). Autolo-
gous blood clot and gelfoam could 
be used as embolizing agents with a 
temporary occlusion capability on the 
arteries. Since the blood clot lyses im-
mediately after the embolization, the 
chance of arterial thrombosis after 
several sessions of TACE is small (20). 
In a randomized trial (21), the hepat-
ic artery remained patent for a longer 
time with blood clot than with gelatin 
sponge, but there was no difference in 
survival. On the other hand, a perma-
nent or semipermanent arterial occlu-
sion with more distal obstruction can 
be achieved with PVA particles, due to 
their smaller size ranging from 50 to 
250 µm in diameter (22) . Brown et al. 
(10) defined no significant difference 
in survival between gelfoam powder 
group and PVA group. Furthermore 
the number of TACE sessions was sig-
nificantly greater in the gelatin sponge 
group than in the PVA group (mean 
2.2 vs. 1.6; P = 0.01). We also found 
no difference in survival between the 
PVA and gelfoam groups. Furthermore 
no difference was found between the 
gelfoam and PVA groups regarding the 
number of TACE sessions (mean 1.7 vs. 
1.4; P = 0.18). Brown et al. (10) used 
gelfoam powder (<1 mm diameter), 
while we used gelfoam particles (1–2 
mm diameter) as the embolic agent 
in TACE. Hence, size difference can be 
the reason of low number of TACE ses-
sions needed in the gelfoam group in 
our study. Gelfoam occludes the artery 
temporarily with recanalization taking 
place within two weeks (23). On the 
other hand, PVA is generally consid-
ered to be a permanent or semiperma-
nent embolic agent, which is used not 
only in TACE but also in other proce-
dures such as uterine artery emboliza-
tion. However, occlusion of the feed-
ing artery for a shorter period of time 
can be sufficient to achieve satisfactory 
ischemia to overcome cell pumps that 
normally expel the chemotherapeutic 
agents, and result in sufficiently high 
level of chemotherapeutics to cause 
tumor necrosis (12). The duration of 
vascular occlusion needed to induce 
tumor necrosis is not well known. In 
pathological analysis of tumors resect-
ed approximately 55 days after TACE, 
gelfoam sponge led to a six-fold in-
crease in cisplatin retention in the tu-
mor compared with the surrounding 
noncancerous liver tissue; 15 of the 20 
index HCCs were completely necrotic 
and the remaining five demonstrated 
70%–90% necrosis (24). Moreover, not 
all arteries occluded with gelfoam re-
canalize, and a permanent occlusion 
rate is about 19% (25). This can ex-
plain the insignificant difference be-
tween gelfoam and PVA groups in the 
current study. 
Stuart et al. (26) used gelfoam pow-
der as an embolic agent and reported 
an overall survival time of 16 months 
in 52 patients. Early (30-day) mortal-
ity rate was 17% in that trial. Brown 
et al. (10) reported an overall survival 
period of 17 months for both gelfoam 
and PVA groups with an early mortali-
ty rate of 2% and 5%, respectively. In 
our study overall survival period was 
15 months for the gelfoam group and 
14 months for the PVA group, with an 
early mortality rate of 10% and 16%, 
respectively. Early mortality rates were 
similar between the gelfoam group and 
the PVA group. High mortality rates 
observed by Stuart et al. (26) and our 
study group can be explained by the in-
clusion of patients with Child-Pugh C 
and segmental portal vein thrombosis 
in the TACE procedure. Additionally, 
patients with bilobar disease were treat-
ed in two lobar infusions separated by a 
few days in their study. However, most 
operators performing TACE in bilobar 
disease separate treatment sessions by a 
minimum of four weeks (27). 
Survival rates were significantly bet-
ter in patients who experienced no 
complications compared with patients 
who had complications. This can be 
explained by the duration of TACE ses-
sion, tumor size and Child-Pugh class, 
since high number of TACE sessions, 
big tumor size and low Child-Pugh 
class can increase the complication 
rates. To our knowledge, no previous 
study in the literature investigated the 
effect of complications on survival 
rates, and further studies are required 
to shed more light on this issue. 
In terms of the number of HCC foci, 
patients with ≤3 HCC nodules had 
significantly better survival rates than 
patients with >3 HCC nodules. There 
was also a significant relationship be-
tween the number of HCC foci and 
AFP levels, since more tumor foci in-
duce higher AFP levels, which depicts 
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higher tumoral activity. Furthermore 
high number of HCC foci means more 
TACE sessions or selective emboliza-
tion, thus the tumor response and 
patient outcome can be affected neg-
atively. Llad et al. (28) defined a sig-
nificant relationship between the AFP 
level (cutoff level, 400 ng/mL) and 
survival in 143 HCC patients; a similar 
relationship was also observed in our 
study, where patients with AFP ≤400 
ng/mL had better survival than those 
with AFP >400 ng/mL. Llovet et al. 
(5) stated that tumor response affects 
the survival. Llad et al. (28) reported 
a positive relationship between the 
reduced tumor size and survival. We 
also determined a significant effect 
of tumor response on survival; thus, 
complete response should be the main 
goal in TACE for an effective treatment 
and better survival. Complete tumor 
response had a significant positive re-
lationship with type 1 lipiodol accu-
mulation and both of them influenced 
survival significantly. It can be specu-
lated that if a type 1 lipiodol accumula-
tion is seen on unenhanced follow-up 
CT after the TACE, one can expect a 
better tumor response and survival. Al-
though superselective embolization in-
dicated type 1 lipiodol accumulation, 
it had no significant effect on survival 
in our study. Bouvier et al. (11) report-
ed similar results in their retrospective 
study. On the other hand, several stud-
ies revealed significant improvement 
on survival with more selective tech-
niques, and recommended the use of 
these techniques in TACE for better 
tumor response and patient outcome 
(11, 15, 29). Age of the patient is an 
important factor on tumoral invasion, 
recurrence risk, metastatic potential, 
survival and prognosis of disease (30). 
Several studies defined better survival 
rates at older ages, since younger pa-
tients have more agressive disease with 
a higher grade of HCC at the time of 
diagnosis (31). In our study we also ob-
served better survival rates in patients 
over 60 years of age. 
This retrospective study has several 
major limitations. Our study popula-
tion is relatively small. Retrospective 
assesment of the subjects limited the 
scientific impact of the results and 
did not allow the randomization of 
patients. Thus, our results need to be 
validated with further prospective ran-
domized control trials on larger series. 
In conclusion, using different em-
bolic agents for TACE had no signif-
icant effect on survival. Although 
PVA group had slightly better surviv-
al rates than gelfoam group, this can 
be attributed to the greater number of 
Child-Pugh A patients in PVA group 
than in gelfoam group. Further trials 
should be focused on the effect of dif-
ferent embolic agents on survival fol-
lowing TACE. Superselective technique 
should be preferred in TACE for better 
tumor response and improved patient 
outcome. Tumor response, number of 
HCC foci, patient age, serum AFP level, 
lipiodol accumulation type, and com-
plications due to TACE had a signifi-
cant effect on survival in HCC treated 
with TACE. 
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